Evidence Table 72. KQ2—Continuous data—Bleeding time

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Svaneborg 200264  parallel | At low risk for CHD (0-1 risk factors) | ASA | 100 | Omega-3 (EPA, DHA, or both). | 12 | BP cuff 40 mm Hg- incisions with parallel to the fold of the elbow | Median 9.6  Lower: 7.6  Upper: 11 | P: <0.05 | NR | p value is for before the injection of ASA | medium |
|  | Placebo | 6 | Median 7.9  Lower: 6.3  Upper: 11.5 | P: <0.05 |  |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | Total Cholesterol (mmol/l) | Mean: 3.4  SD: 0.7 | NR | NR | No significant differences between groups. | NA |
| At high risk for CHD | Statins | 20 | placebo | 169 | Mean: 3.4  SD: 0.7 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | LDL-C (mmol/l) | Mean: 1.7  SD: 0.5 | NR | NR | No significant differences between groups. | Low |
|  | Placebo | 169 | Mean: 1.8  SD: 0.5 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | HDL-C (mmol/L) | Mean: 1.1  SD: 0.3 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Mean: 1.1  SD: 0.2 | NR | NR |

| Evidence Table 72. KQ2—Continuous data—Bleeding time (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | Triglyceride (mmol/l) | Median: 1.1  IQR, lower limit: 0.8  IQR, upper limit: 1.5 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Median: 1.5  IQR, lower limit: 1.1  IQR, upper limit: 2.3 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | Systolic blood pressure (mmHg) | Mean: 142  SD: 17 | NR | NR | No significant differences between groups. | Low |
| Placebo | 169 | Mean: 143  SD: 21 | NR | NR |
| Neil, HAW 201053 | At high risk for CHD | Statins | 20 | Omega-3 | 163 | Diastolic blood pressure | Mean: 80  SD:11 | NR | NR | No significant differences between groups. | NA |
| Placebo | 169 | Mean: 80  SD: 12 | NR | NR |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Ivy method - bleeding time was the time between first and last extravasations and value was mean of three bleeding times | Mean: 6.3  SD: 3.1 | Mean: .21 | Mean: 1.01 | ratio of means presented with 90% CI | low-medium |
|  | Placebo | 50 | Mean: 6.2  SD: 3.8 | Mean: 2.1 |
| Hansen 199329  crossover | Low and/or Moderate | lovastatin | 40 | Fish/marine oils | 14 | NR | Mean: 390  Median  SD: 150  SE:  Lower:  Upper: | NR | NR | Reported in graphical form only. | medium |
|  | Placebo | 14 | Mean: 330  Median  SD: 70  SE:  Lower:  Upper: | NR |
| Kim 201035  crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | determined just before dosing and at 5, 12, and 48 hours after dosing. While applying 40 mm Hg of pressure on the upper arm, we made an incision using a bleeding-time measurement device (Surgicutt, International Technidyne Corp., Edison, New Jersey) on the volar surface of the forearm to measure the bleeding time. | Mean: 6.3  Median  SD: 2.3  SE:  Lower:  Upper: | Mean:1.1  % mean:  Median:  SD:  P: | NR | Range of mean: ginkgo group 3-11.5; To treatment group 2.5-8.5. | medium |
|  | No treatment | 24 | Mean: 5.3  Median  SD: 1.7  SE:  Lower:  Upper: | Mean:0.9  Median:  SD:  P:  <0.05 |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | measured 0 and 6 h after drug administration by Ivy’s method | Mean: 211  Median  SD: 70  SE: 25  Lower:  Upper: | NR | NR | 95% CI of mean for individual group data: ginkgo group: 153.00-270.00; No treatment group: 118.00-182.00. | medium |
|  | No treatment | 10 | Mean: 150  Median  SD: 42  SE: 14  Lower:  Upper: | NR |
| Aruna 20072  crossover | At low risk for CHD (0-1 risk factors) | Clopidogrel 75 mg | 105 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | measured 0 and 6 h after drug administration by Ivy’s method | Mean: 148  Median  SD: 78  SE: 28  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | 95% CI of mean for individual group data: ginkgo group: 83.00-213.00; No treatment group: 91.00-190.00. | medium |
|  | No treatment | 10 | Mean: 141  Median  SD: 59  SE: 21 | NR |
| Mueller 199151  crossover | Low and/or Moderate | aspirin | 325 - single dose | Fish/marine oils | 12 | measured using a Simplate II system. By blinded operator. | Mean: 680  Median  SD: 302.6  SE:  Lower:  Upper: | Mean:  % mean: 18.6  Median:  SD:  P: | NR |  | medium |
|  | Placebo | 12 | Mean: 633.8  Median  SD: 339.8 | Mean:  % mean: 14.5 |